KOSDAQ - Delayed Quote KRW

PharmaResearch Co., Ltd. (214450.KQ)

434,000.00
+10,500.00
+(2.48%)
As of 9:53:51 AM GMT+9. Market Open.
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
350,115,068.64
350,115,068.64
261,010,910.56
194,758,643.93
154,082,897.89
Cost of Revenue
98,877,811.42
98,877,811.42
70,752,514.45
53,245,714.39
45,750,356.15
Gross Profit
251,237,257.22
251,237,257.22
190,258,396.11
141,512,929.54
108,332,541.74
Operating Expense
125,186,500.02
125,186,500.02
98,000,609.41
75,596,777.65
55,843,645.71
Operating Income
126,050,757.20
126,050,757.20
92,257,786.70
65,916,151.89
52,488,896.03
Net Non Operating Interest Income Expense
5,085,206.28
5,085,206.28
4,415,900.92
1,441,582.72
2,412,145.30
Pretax Income
115,812,758.33
115,812,758.33
100,704,567.36
54,048,007.70
56,033,421.12
Tax Provision
26,869,722.71
26,869,722.71
23,439,914.91
10,613,903.80
9,209,784.09
Net Income Common Stockholders
92,043,313.16
92,043,313.16
76,551,213.75
40,576,699.24
46,688,655.71
Basic EPS
8.94k
--
7.57k
4.07k
4.72k
Diluted EPS
8.94k
--
7.50k
4.07k
4.71k
Basic Average Shares
10,294.52
--
10,111.11
9,977.06
9,898.75
Diluted Average Shares
10,294.52
--
10,204.11
9,977.06
10,052.65
Total Operating Income as Reported
126,050,757.12
126,050,757.12
92,257,786.62
65,916,151.83
52,488,896.04
Rent Expense Supplemental
329,021.66
329,021.66
-127,774.17
-139,538.77
42,217.29
Total Expenses
224,064,311.44
224,064,311.44
168,753,123.86
128,842,492.04
101,594,001.86
Net Income from Continuing & Discontinued Operation
92,043,313.16
92,043,313.16
76,551,213.75
40,576,699.24
46,688,655.71
Normalized Income
111,995,314.73
111,995,314.73
73,504,809.90
49,337,883.14
46,717,856.58
Interest Income
10,174,067.67
10,174,067.67
7,403,096.46
5,271,646.31
3,725,833.39
Interest Expense
4,634,271.39
4,634,271.39
2,987,195.57
3,830,063.59
1,313,688.10
Net Interest Income
5,085,206.28
5,085,206.28
4,415,900.92
1,441,582.72
2,412,145.30
EBIT
120,447,029.72
120,447,029.72
103,691,762.93
57,878,071.29
57,347,109.22
EBITDA
134,092,263.43
134,092,263.43
115,687,359.36
68,480,022.79
66,899,507.75
Reconciled Cost of Revenue
98,877,811.42
98,877,811.42
70,752,514.45
53,245,714.39
45,750,356.15
Reconciled Depreciation
13,645,233.71
13,645,233.71
11,995,596.43
10,601,951.50
9,552,398.53
Net Income from Continuing Operation Net Minority Interest
92,043,313.16
92,043,313.16
76,551,213.75
40,576,699.24
46,688,655.71
Total Unusual Items Excluding Goodwill
-25,979,508.35
-25,979,508.35
3,970,596.80
-10,902,136.62
-34,944.42
Total Unusual Items
-25,979,508.35
-25,979,508.35
3,970,596.80
-10,902,136.62
-34,944.42
Normalized EBITDA
160,071,771.78
160,071,771.78
111,716,762.56
79,382,159.41
66,934,452.17
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-6,027,506.78
-6,027,506.78
924,192.95
-2,140,952.72
-5,743.55
12/31/2021 - 7/24/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

130A.T VERITAS IN SILICO INC
645.00
+0.78%
 
7774.T Japan Tissue Engineering Co., Ltd.
583.00
-1.36%
 
145020.KQ Hugel, Inc.
351,500.00
+1.59%
 
203400.KQ ABION Inc.
6,950.00
+7.25%
 
000504.SZ Landfar Bio-medicine Co., Ltd
6.77
+1.50%
 
344860.KQ INNOGENE Co.,Ltd.
2,515.00
-2.71%
 
475960.KQ TOMOCUBE
28,900.00
-1.03%
 
086900.KQ Medy-Tox Inc.
169,400.00
+0.71%
 
CONCORDBIO.BO Concord Biotech Limited
1,506.55
+0.03%
 
4565.T Nxera Pharma Co., Ltd.
818.00
-1.92%